Background: Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are used in diagnosing preeclampsia (PE), but their potential in early prediction in pregnant women at 16 to 20 weeks gestation (WG) has remained unexplored.
The criteria generally used for the diagnosis of PE are blood pressure of 140/90 mmHg or greater on 2 occasions that are 2 hours apart and proteinuria greater than 0.30 g per 24-hour period. The diagnosis of PE remains challenging because the aforementioned criteria are nonspecific and can lead to misclassification. [3] [4] [5] Although the pathophysiologic characteristics of PE are not completely clear, an imbalance of placental angiogenic factors plays an important role in the pathogenesis of PE. 4 In the past decade, several clinical studies [2] [3] [4] [5] [6] [7] were designed to evaluate the predictive value of angiogenic factors as prediction tests of PE. The factors studied most extensively are the antiangiogenic protein, soluble fms-like tyrosine kinase-1 (sFlt-1), the proangiogenic protein, placental growth factor (PlGF), and soluble endoglin. Women with PE have various levels of these proteins, and the differences correlate with the severity of the disease. Alterations of these factors occur several weeks before clinical manifestation of PE. 3, 6, 8 No substantial differences were observed
In a healthy pregnancy, the concentration of PlGF increases during the first 2 trimesters and decreases when birth is near. In contrast, the level of sFlt-1 remains stable during the early and middle stages of pregnancy and continues to increase steadily until birth. 10 The level of sFlt-1 was found to be higher and the level of PlGF lower in the group of women with PE, compared with a group with healthy pregnancy. The sFlt-1/PlGF ratio is even more strongly associated with PE and it was higher in the PE group. 7 Typically, PlGF and sFlt-1 are analyzed in serum; however, Tang et al 11 reported good correlation between values of PlGF and sFlt-1 in serum and urine.
A number of studies about sFlt-1 and PlGF have been performed in women in the late phase of pregnancy, mostly at longer than 24 WG, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [12] [13] [14] [15] in which the clinical significance of both parameters was clearly proven. A study by Zeisler et al 16 was designed to derive and validate a cut-off point of the sFlt-1/PlGF ratio in a 2-phase approach. This study used data from more than 1000 participants from 14 countries. The cut-off values gained from this and other studies were later investigated in the literature. 17, 18 Other studies concentrated on sFlt-1 and PlGF values in the first trimester of pregnancy. 9, [19] [20] [21] [22] [23] [24] [25] The results obtained from these studies have been ambiguous. To our knowledge, none of the studies we reviewed except Chuchracki et al 19 addressed the levels of these factors in the second trimester of pregnancy.
Our study reflects sFlt-1 and PlGF values and the sFlt-1/ PlGF ratio in a group of pregnant women with PE and a control group with normal pregnancies, all at 16 to 20 WG. This type of cohort has not clearly been examined in the literature; findings in this group could be crucial for early diagnostic of PE.
Materials and Methods
In the present retrospective study, we measured serum levels of sFlt- The group of women with PE included 16 cases of early-onset (≤34 WG) and 23 cases of late-onset (>34 WG) PE. A total of 41% of the women were older than 30 years (36% in the group with PE vs 43% in the group without PE). None of these women were younger than 18 years. PE first appeared at 30 WG-the median was 35 WG (95% CI, 33.9-37 WG).
We used serum specimens to determine sFlt-1 and PlGF values. Automatic analyses were carried out on the immunochemical module of the cobas 8000 (F. Hoffman-La Roche Ltd.; hereinafter, Roche) via electrochemiluminiscence noncompetitive immunoassay. Details about methodologies are given in Roche inserts for both tests. 26 Statistical analyses were performed using Medcalc statistical software, version 9.3.2.0 (MedCalc Software). The differences were calculated via Mann-Whitney test and receiver operating characteristic (ROC) analysis. All P values were 2-tailed.
The study, performed in accordance with the Declaration of Helsinki and institutional policies, was approved by the local Ethical Committee. Written informed consent was obtained from all individuals included in this study.
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Results
Medians and confidence intervals (CIs) for sFlt-1, PlGF, and the sFlt-1/PlGF ratio in controls and in the group of women in whom PE later developed, both groups of which were at 16 to 20 WG, are given in Table 1 . Differences are described by 2-tailed probability. Calculations were performed via Mann-Whitney testing.
The median values for serum concentration for sFlt-1 and the sFlt-1/PlGF ratio in pregnant women with PE were significantly higher than those of the women in the control group. In contrast, the median serum concentration of PlGF in individuals with PE was significantly lower.
The diagnostic accuracy of sFlt-1, PlGF, and the sFlt-1/PlGF ratio in PE was calculated by ROC in the aforementioned groups of women (39 with PE, 81 controls) at 16 to 20 WG. Additional data are given for women with early-onset PE at 34 WG or more (16 with PE, 81 controls)-see Table 2 and Figure 1 . Table 3 .
Discussion
The results of the determination of sFlt-1/PlGF for pregnant women at more than 24 WG are well investigated and already used in medical practice. However, the significance of sFlt-1 and PlGF testing in the first trimester remains unclear and seems to be too early to be useful. Despite that, according to the literature, 25 It is greatly important to test for PE before 20 WG. 6 Thus, performing the initial analysis of sFlt-1 and PlGF at 16 to 20 WG seems to be appropriate.
In this study, we emphasized correct diagnosis of individual participants, to yield the most accurate evaluation. It turned out that the diagnosis established during pregnancy can be modified. For example, after preeclamptic seizure, the diagnosis of hypertension was changed to that of PE. In other cases, the original diagnosis of PE was not confirmed, and it was found that the hypertension or proteinuria had occurred due to other causes. For these reasons, we included women in our study cohort only after delivery and affirmation of diagnosis. The measured results confirmed that compared with healthy pregnancy, the level of sFlt-1 in serum of women in whom PE later developed had increased (P <.001), the levels of PlGF had decreased (P = .001) and in particular, the sFlt-1/PlGF ratio was higher (P <.001) as soon as 16 to 20 WG. The measured results corresponded with the severity of the disease and depended on whether it was early-or late-onset PE. The group of women with early-onset PE had a significantly higher sFlt-1/PlGF ratio, compared with the values of all the women with PE.
The area under the curve (AUC) and diagnostic sensitivity and specificity, calculated using ROC analysis, confirmed the assumption, in accordance with the literature, 6 that among monitored parameters sFlt-1, PlGF, and sFlt-1/ PlGF, the sFlt-1/PlGF ratio exhibited superior performance, reaching an AUC of 0.863 (95% CI, 0.788-0.918), sensitivity of 74.4%, and specificity of 86.6%. For the early-onset PE group, the AUC for sFlt-1/PlGF was 0.970 (95% CI, 0.913-0.994), sensitivity of 100%, and specificity of 81.5%, respectively. These values show that all participants with early PE had a ratio of sFlt-1/PlGF higher than the criterion (cut-off) value of 17, as proposed from ROC-analysis results.
Using cut-off values calculated from the group of healthy pregnant women ( percentile for PlGF (57 pg/mL)-12 of 39 women in whom PE later developed would be incorrectly diagnosed at 16 to 20 WG as not having PE. Data show that analyses were carried out too early: none of the parameters-sFlt-1, PlGF, and sFlt-1/PlGF-were pathological in those 12 women. A different situation was present in the group with early-onset PE-using calculated cut-off values, only 2 of 16 women would be incorrectly classified as not having PE.
Therefore, early-onset PE (<34 WG) has been clearly distinguishable at 16 to 20 weeks of pregnancy. About half (11 of 23) of the women with late-onset PE showed pathology in the sFlt-1/PlGF ratio and 1 of 2 other parameters (sFlt-1 or PlGF; data not shown).
Consequently, analysis of the angiogenic factors sFlt-1, PlGF, and sFlt-1/PlGF ratio enables medical professionals to recognize PE as soon as 16 to 20 WG and can be used in clinical practice. This information is important because to our knowledge, it has not yet been clearly proven in the published literature. Contrary to the claim 9 that PE cannot be distinguished by angiogenic factors earlier than 5 weeks before onset, we were able, according to our data, to predict PE at 10 to 15 weeks before onset.
Our results, therefore, indicate that analysis of sFlt-1/PlGF at 16 to 20 WG could be recommended for women with high potential risk of PE because in our cohort, results of those analyses could predict the development of PE. Many PE cases occur close to term, and late PE is associated with maternal morbidity and mortality due to the eventual development of eclampsia. As a result, we propose to perform, at minimum, 1 additional test of sFlt-1 and PlGF values at 25 to 30 WG and to evaluate the results using specific cut-off values for given weeks of gestation (there are different cut-offs for different ranges of WG; the results are divided separately from 24-28 WG, 29-34 WG), as presented in the literature. 26 Although analysis of sFlt-1 and PlGF is expensive, the proof of diagnosis of PE according to levels of PlGF and sFlt-1 could influence the decision of whether hospitalization of certain patients is necessary and therefore could decrease the budget. 28 Zeisler et al 16 suggest using universal cut-offs independent of gestational weeks, which greatly simplifies the situation but is suitable for short-term prediction of PE only. The information regarding cut-off values for pathology of sFlt-1, PlGF, and sFlt-1/PlGF for different gestational weeks, as calculated in the Roche insert 26 or in our study, helps to establish diagnosis of PE more precisely.
In conclusion, sFlt-1, PlGF, and the sFlt-1/PlGF ratio are superior to conventional biochemical markers of proteinuria, uric acid, and aminotransferases because the pathologies of these conventional parameters are not manifested until after 20 WG and usually occur later in an advanced stage of pregnancy and only in some women with PE. In the presented study, in a group of women in whom PE later developed, at 16 to 20 WG, only 5.0% of participants had an increased AST level; for the group of women with early-onset PE (Supplemental Table 1 ), that value was 6.3%. No other conventional biochemical marker was pathological in this phase of pregnancy.
We stress that sFlt-1 and PlGF are not eligible parameters to be tested within screening in pregnancy in general but only for individuals with increased chance of PE.
The small sample size in the PE group could be a limitation of the present study and deserves further consideration. The presented results are for specimens from women at 16 to 20 WG only, whereas in practice, sFlt-1 and PlGF also should be measured in any gestational week/range of weeks in which PE has developed. The proposed cut-off for 16 to 20 WG, taken from our ROC analysis and calculated from the 95 th percentile in healthy pregnant women (sFlt-1/ PlGF ratio of 17 and 23, respectively) differ slightly. In the future, a single cut-off value should be established.
In our opinion, sFlt-1 and PlGF are interesting prospective markers of PE. The presented results show that the values of these parameters and, in particular, their ratio, compared with conventional laboratory test results, can detect PE as early as 16 to 20 WG-10 to 15 weeks before PE onset. This finding is important because the sooner PE is diagnosed, the greater the chance to minimize its consequences for mother and child. LM 
